• Histologically confirmed B-cell non-Hodgkin's lymphoma including the following types

‣ diffuse large B-cell lymphoma

⁃ high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement

⁃ transformed lymphoma

⁃ primary mediastinal large B-cell lymphoma

⁃ follicular lymphoma (FL)

• Relapsed or refractory diseases fulfilling one of the following criteria (individuals must have received anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen)

‣ Primary refractory disease, defined as disease progression after first-line immunochemotherapy or disease progression within 6 weeks of the end of the last chemotherapy

⁃ Stable disease (SD) as best response after at least 4 cycles of first-line therapy

⁃ Partial response (PR) as best response after at least 6 cycles of first-line therapy (biopsy-proven residual disease is needed for individuals with Deauville score of 4)

⁃ PR as best response after at least 2 cycles of second-line therapy

⁃ Disease relapse ≤12 months after the completion of first-line immunochemotherapy

⁃ Relapsed or refractory disease after ≥2 lines of chemotherapy

• Presence of at least one of the following high-risk prognostic factors: (1) extranodal involvement; (2) maximum diameter of the bulky mass ≥5 cm; (3) TP53 gene alterations

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

• Eligible for HDCT/ASCT based on the investigator's assessment and are scheduled to undergo an ASCT sequential CAR-T treatment regimen

• Adequate renal and hepatic function defined as:

‣ Serum alanine aminotransferase (ALT/AST) ≤ 3 upper limit of normal (ULN)

⁃ Total bilirubin ≤1.5 mg/dL(\<3 times ULN in patients with Gilbert's syndrome, cholestasis due to hepatoportal compression adenopathy, biliary obstruction in patients with liver involvement or lymphoma)

⁃ Serum creatinine ≤1.5 ULN, or creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min

• Cardiac ejection fraction ≥ 40%

• Baseline oxygen saturation \> 95% on room air

• Life expectancy ≥3 months